AVEO Oncology (AVEO) Announces Addition of FOTIVDA into National Comprehensive Cancer Network Clinical Practice Guidelines

Go back to AVEO Oncology (AVEO) Announces Addition of FOTIVDA into National Comprehensive Cancer Network Clinical Practice Guidelines

AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines

March 29, 2021 7:00 AM EDT

BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved FOTIVDA for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth... More